Usefulness of Tolvaptan preventing for excessive body fluid retension after cardiac surgery

Usefulness of Tolvaptan preventing for excessive body fluid retension after cardiac surgery - Usefulness of Tolvaptan preventing for excessive body fluid retension after cardiac surgery

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000013153

Enrollment

Registered

2014-03-01

Start date

2014-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

valvular heart disease, ischemic heart disease, aortic aneurysm, aortic dissection, cardiac tumor

Interventions

oral furosemide at a dose of 10-20mg and oral tolvaptan at a dose of 7.5mg daily oral furosemide at a dose of 10-20mg daily

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)patients perfomed cardiac surgery using artificial cardiopulmonary device 2)patients received explanation enough and obtained its consent in a sentence

Exclusion criteria

Exclusion criteria: 1)patients have hypersensitivity to this agent or similar medicine 2)anuria 3)hypernatremia 4)pregnant patients 5)malignant tumor 6)severe hepatopathic patients 7)dialysis patients 8)If the attending physician determines that the patient is an inadequate.

Design outcomes

Primary

Measure	Time frame
volume of urine , change of body weight, abnormality of the electrolyte	—

Countries

Japan

Contacts

Public ContactSawaka Tanabe

University of Fukui Department of Cardiovascular Surgery

tanabes@u-fukui.ac.jp0776-61-3111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026